Boothbay Fund Management’s Alto Neuroscience ANRO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.8M Sell
106,234
-33,070
-24% -$765K 0.04% 569
2026
Q1
$3.13M Hold
139,304
0.04% 460
2025
Q4
$2.48M Buy
139,304
+106,832
+329% +$1.35M 0.04% 499
2025
Q3
$131K Hold
32,472
﹤0.01% 1703
2025
Q2
$71.4K Sell
32,472
-23,660
-42% -$56.3K ﹤0.01% 1329
2025
Q1
$121K Sell
56,132
-46,968
-46% -$168K ﹤0.01% 1217
2024
Q4
$436K Buy
+103,100
New +$643K 0.01% 929

Other funds holding ANRO

Boothbay Fund Management's ANRO Position: Q2 2026 in Review

Boothbay Fund Management reduced its Alto Neuroscience (ANRO) stake by 24% in Q2 2026, selling an estimated $765K and leaving 106,234 shares worth $2.8M. The position accounts for 0.04% of the portfolio, ranked #569.

Boothbay Fund Management first reported a position in ANRO in Q4 2024 and has held it in 7 quarters since. The position peaked at $3.13M in Q1 2026. 114 funds tracked by Wall St. Rank hold ANRO as of Q2 2026.

  • Boothbay Fund Management held 106,234 shares of Alto Neuroscience worth $2.8M as of Q2 2026.
  • Boothbay Fund Management sold 33,070 Alto Neuroscience shares in Q2 2026, an estimated $765K.
  • Alto Neuroscience made up 0.04% of Boothbay Fund Management's portfolio in Q2 2026, its #569 holding.
  • Boothbay Fund Management first reported a position in Alto Neuroscience in Q4 2024 and has held it in 7 quarters since.
  • Boothbay Fund Management's Alto Neuroscience position peaked at $3.13M in Q1 2026.
  • 114 funds tracked by Wall St. Rank held Alto Neuroscience as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.